Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / COM
-
Number of holders
-
62
-
Total 13F shares, excl. options
-
11.9M
-
Shares change
-
+3.72M
-
Total reported value, excl. options
-
$17.6M
-
Value change
-
+$1.91M
-
Put/Call ratio
-
0.19
-
Number of buys
-
48
-
Number of sells
-
-33
-
Price
-
$1.48
Significant Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q2 2025
98 filings reported holding PLX - Protalix BioTherapeutics, Inc. - COM as of Q2 2025.
Protalix BioTherapeutics, Inc. - COM (PLX) has 62 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.9M shares
.
Largest 10 shareholders include BlackRock, Inc. (3.37M shares), RENAISSANCE TECHNOLOGIES LLC (1.62M shares), NORTHERN TRUST CORP (1.08M shares), GEODE CAPITAL MANAGEMENT, LLC (826K shares), Connor, Clark & Lunn Investment Management Ltd. (496K shares), VANGUARD GROUP INC (485K shares), MORGAN STANLEY (462K shares), STATE STREET CORP (444K shares), Stratos Wealth Partners, LTD. (350K shares), and SUSQUEHANNA INTERNATIONAL GROUP, LLP (299K shares).
This table shows the top 62 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.